BioSource International has appointed John Zabriskie to its board of directors, the Camarillo, Calif.-based company said last week. Zabriskie currently serves as president of Lansing Brown Investments. In previous positions, Zabriskie has served as president, CEO, and chairman of the board of directors of NEN Life Science Products, and as president and CEO of Pharmacia and Upjohn. BioSource sells reagent systems for functional genomics, proteomics, and other drug discovery applications.
PerkinElmer has juggled some names at the top, replacing life sciences executive vice president John Engel with Peter Coggins, who will hold the title president of life sciences. Engel, who oversaw PerkinElmer’s acquisition of Packard Biosciences, will now serve as executive vice president of operations at PerkinElmer.
Coggins comes to PerkinElmer from Amersham Biosciences, where he was executive vice-president of global sales and marketing. Coggins also served as chairman of the board for Amersham Japan KK, Amersham’s Japanese subsidiary. Coggins has also worked in sales and marketing at ICN Biomedicals, Labsystems Oy, and Amersham International.
Coggins received his PhD in zoology from Chelsea College, University of London.
Elizabeth Hill has joined Cambridge, UK-based 3D Molecular Sciences as CEO. Hill most recently ran her own consultancy business providing mentoring services and funding to startup technology companies. 3D, a spin-out from The Generics Group, Imperial College Innovations, and the University of Hertfordshire, has developed technology for using optically readable microscopic particles and 3D bead-based arrays for applications in genomics and proteomics.
Blizzard Genomics has appointed James Adam as CEO, succeeding Martin Blumenfeld, the company’s founder. Adam joined Blizzard in March 2001 as president, and will continue to hold that title in addition to serving on the board of directors and as CEO.
In previous positions, Adam held various management positions with Ican, MGI Pharma, and KPMG Peat Marwick. He also founded Adam Consulting, a firm providing services to startups.
Blumenfeld will remain with the company as chief scientific officer and chairman of the board of directors. St. Paul, Minn.-based Blizzard is developing analysis instrumentation and software for DNA and protein analysis.
Roberto Cetrullo has joined Human Genome Sciences as vice president for business development, the Rockville, Md.-based company said last week. Cetrullo, who most recently served as vice president for business development for the US medicines group of Bristol-Myers Squibb, will report to Ellen Baron, HGS’ senior vice president for business development.
In previous positions at Bristol-Myers, which he joined in 1985, Cetrullo has served as director for worldwide strategic product planning for antivirals and immunologicals and director for corporate development with responsibility for Latin America.